RBGLY - Reckitt Benckiser Group plc

Other OTC - Other OTC Delayed Price. Currency in USD
+0.05 (+0.31%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close16.33
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.32 - 16.41
52 Week Range14.64 - 18.67
Avg. Volume562,677
Market Cap58.893B
Beta (3Y Monthly)0.97
PE Ratio (TTM)6.74
EPS (TTM)2.43
Earnings DateN/A
Forward Dividend & Yield0.53 (3.25%)
Ex-Dividend Date2019-04-22
1y Target Est13.85
  • Promescent CEO Jeff Abraham on his $150 million legal battle over trade secrets
    CNBC2 months ago

    Promescent CEO Jeff Abraham on his $150 million legal battle over trade secrets

    Promescent CEO Jeff Abraham details the company's lawsuit against consumer giant Reckitt Benckiser for $150 million, alleging fraud and theft of trade secrets.

  • PR Newswireyesterday

    Johnson Fistel, LLP Announces Investigations of Beazer Homes USA, Inc., NIO Inc., and Reckitt Benckiser Group plc; Encourages Investors Who Suffered Losses to Contact the Firm

    SAN DIEGO , May 25, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: Beazer Homes USA , Inc. (NYSE: BZH) [click here ...

  • Reuters17 days ago

    Reckitt chairman aims for swift decision on CEO succession

    Reckitt Benckiser is working to resolve both its search for a new chief executive and its position relating to U.S. charges of wrongdoing at a former business, its chairman told investors at its annual general meeting on Thursday. The maker of Lysol cleaners and Durex condoms is "well under way with a comprehensive process" to select a successor to Chief Executive Rakesh Kapoor, Chairman Christopher Sinclair said at the meeting in London. "I'm hopeful that in the not-too-distant future, we'll have something significant to report here," Sinclair said.

  • Healthier People Are a Problem For Reckitt
    Bloomberg24 days ago

    Healthier People Are a Problem For Reckitt

    Not for Reckitt Benckiser Group Plc, which reported weaker-than-expected first-quarter sales on Thursday. All this means Reckitt will find it a bit harder to achieve its full-year target of 3-4 percent like-for-like sales growth. It may get some help from infant nutrition, where sales growth of 5 percent indicates that the division is recovering from a disruption to baby milk supplies last year.

  • Reuters24 days ago

    Reckitt Benckiser first-quarter sales fall short, sees better second half

    Reckitt Benckiser Group reported lower-than-expected first-quarter sales, due to weakness in its health business, but stood by its full-year forecast, relying on an improvement as the year goes on. Like-for-like sales rose 3 percent in Reckitt's hygiene and home business, but were flat in health as a 5 percent rise in infant formula was offset by a 9 percent drop in over-the-counter medicines. Other health products, including Airborne vitamins and Scholl footcare products, were flat.

  • Estee Lauder (EL) Hits Fresh High: Is There Still Room to Run?
    Zackslast month

    Estee Lauder (EL) Hits Fresh High: Is There Still Room to Run?

    Estee Lauder (EL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

  • Bloomberglast month

    Opioid Crisis Threatens Reckitt's Reinvention

    The consumer good group’s strategy now looks to be a hostage to U.S. lawyers. Under outgoing CEO Rakesh Kapoor, Reckitt had been simplifying and refocusing its portfolio. This effort was expected to culminate in the division of the business into two separate companies: one focused on household products such as Cillit Bang cleaner and Finish dishwasher tabs, the other on consumer health treatments like Nurofen painkillers and Gaviscon heartburn tablets.

  • Reuterslast month

    Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

    In an indictment in federal court in Abingdon, Virginia, a grand jury said Indivior made billions of dollars by deceiving doctors and healthcare benefit programs into believing its Suboxone Film version was safer and less susceptible to abuse than similar drugs. The indictment charged Indivior and its subsidiary Indivior Inc with conspiracy, health care fraud, mail fraud and wire fraud. If the company is convicted, the U.S. government would seek forfeiture of at least $3 billion from Indivior, the indictment said.

  • Reckitt Boss Can't Escape the Opioid Abuse Crisis
    Bloomberg2 months ago

    Reckitt Boss Can't Escape the Opioid Abuse Crisis

    There were many reasons for Kapoor and fellow managers to demerge Indivior Plc in 2014. Reckitt got the demerger away before the competition struck. On Wednesday, litigation risk became a stark reality, hitting Indivior and its former parent hard.

  • Reuters2 months ago

    Reckitt plays down Indivior risk to infant formula business

    Reckitt Benckiser Group on Wednesday sought to play down any potential impact to its infant formula business from U.S. litigation against Indivior, which it used to own, saying the risk was theoretical and unlikely. The U.S. Justice Department has accused British drugmaker Indivior of illegally boosting prescriptions for its blockbuster opioid addiction treatment. "As stated in our annual report, this is a theoretical risk but we consider this to be highly unlikely and only a remote possibility," the company said, responding to a question about whether the risk for Reckitt could extend to the infant formula business, which Reckitt bought in 2017.

  • Reuters2 months ago

    FTSE 100 little changed ahead of Brexit summit, Indivior tanks

    The FTSE 100 was marginally lower while the FTSE 250 was up 0.1 percent by 0839 GMT. Markets were largely subdued due to a transatlantic aircraft subsidy dispute, with the U.S. threatening to impose tariffs on $11 billion worth of European Union products. "The market is obviously taking a cautious look at the simmering EU-U.S. trade spat and preparing for a negative outcome but hoping for a happy ending," Markets.com analyst Neil Wilson said.

  • P&G Witnesses Balanced Risk-Reward: Stock Up 31.2% in a Year
    Zacks2 months ago

    P&G Witnesses Balanced Risk-Reward: Stock Up 31.2% in a Year

    P&G (PG) gains from initiatives to improve product, packaging & marketing efforts, and productivity & cost-saving plans. However, strained margins and currency headwinds remain concerns.

  • Reckitt Benckiser CEO gets hefty 2018 pay rise after sales improve
    Reuters2 months ago

    Reckitt Benckiser CEO gets hefty 2018 pay rise after sales improve

    Reckitt Benckiser's Chief Executive Rakesh Kapoor got a 69 percent pay rise last year, following an improvement in the company's performance after three tough years. The British consumer goods maker said on Tuesday in its 2018 annual report that Kapoor received total compensation of 15.2 million pounds in 2018, up from 9.0 million in 2017. Kapoor's 2018 base salary stayed the same, but he received a bonus of 3.4 million pounds, which the company said reflected improved performance.

  • Barrons.com2 months ago

    How a New CEO Could Revive Reckitt Benckiser Stock

    The Anglo-Dutch consumer-goods maker’s growth has slowed in recent years, and the shares have fallen. But now, longtime CEO Rakesh Kapoor is retiring and a new CEO could spark changes.

  • MS Global Franchise Fund's Top 5 Buys of the 4th Quarter
    GuruFocus.com2 months ago

    MS Global Franchise Fund's Top 5 Buys of the 4th Quarter

    Largest buy is major Daniel Loeb holding Baxter